Table 3.
Name | Number of articles | Popularity index (%)* |
---|---|---|
Sumatriptan# | 277 | 4.5 |
Topiramate | 246 | 4.0 |
Divalproex | 104 | 1.7 |
Amitriptyline# | 67 | 1.1 |
Dihydroergotamine# | 67 | 1.1 |
Rizatriptan | 66 | 1.1 |
Propranolol# | 65 | 1.1 |
Naproxen# | 61 | 1.0 |
Ergotamine# | 58 | 1.0 |
Aspirin# | 57 | 0.9 |
Zolmitriptan | 57 | 0.9 |
Acetaminophen# | 54 | 0.9 |
Almotriptan | 52 | 0.8 |
Frovatriptan | 50 | 0.8 |
Flunarizine | 40 | 0.6 |
Gabapentin | 39 | 0.6 |
Ibuprofen# | 36 | 0.6 |
Naratriptan | 29 | 0.5 |
Notes:
Share of all (6,111) migraine-subfield publications in 2009–2013
MeSH term. The following drugs did not reach the 2008–2013 threshold of 0.5% for the whole subfield of migraine: eletriptan 0.4, lamotrigine 0.4, carbamazepine 0.4, verapamil 0.4, metoprolol 0.3, methysergide 0.2, timolol 0.2, fluoxetine 0.2, pregabalin 0.2, atenolol 0.1.
Abbreviation: MeSH, Medical Subject Headings.